Floatz logo

FLUOROURACILUM

Histiocytosis

Institut de Recherches Internationales ServierSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Histiocytosis cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
New York Medical College
Phase 2B
Thiotepa
New York Medical College
Phase 2B
Evomela
New York Medical College
Phase 2B
Fludarabine
New York Medical College
Phase 2B
TACROLIMUS
New York Medical College
Phase 2B

View all 17 →

Same molecule, other indications

FLUOROURACILUM is also rated in:

colon carcinomaDormant
A
Indicative ·
82 / 100
View asset →
Unresectable or Metastatic Colorectal CancerDormant
BBB
Indicative ·
79 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →